Investment Analysts’ Weekly Ratings Changes for Travere Therapeutics (TVTX)

A number of research firms have changed their ratings and price targets for Travere Therapeutics (NASDAQ: TVTX):

• 2/24/2025 – Travere Therapeutics had its price target raised by analysts at Citigroup Inc. from $31.00 to $35.00. They now have a “buy” rating on the stock.
• 2/21/2025 – Travere Therapeutics had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
• 2/12/2025 – Travere Therapeutics had its price target raised by analysts at Scotiabank from $27.00 to $32.00. They now have a “sector outperform” rating on the stock.
• 2/12/2025 – Travere Therapeutics had its price target raised by analysts at Evercore ISI from $33.00 to $45.00. They now have an “outperform” rating on the stock.
• 2/12/2025 – Travere Therapeutics had its price target raised by analysts at Canaccord Genuity Group Inc. from $22.00 to $45.00. They now have a “buy” rating on the stock.
• 1/15/2025 – Travere Therapeutics had its price target raised by analysts at HC Wainwright from $18.00 to $22.00. They now have a “buy” rating on the stock.
• 1/10/2025 – Travere Therapeutics is now covered by analysts at Cantor Fitzgerald. They set an “overweight” rating on the stock.

Travere Therapeutics Price Performance

Shares of NASDAQ:TVTX opened at $20.65 on Wednesday. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. The stock has a market capitalization of $1.61 billion, a PE ratio of -5.04 and a beta of 0.72. The firm’s 50 day moving average price is $19.82 and its 200-day moving average price is $16.86. Travere Therapeutics, Inc. has a twelve month low of $5.12 and a twelve month high of $25.29.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings results on Thursday, February 20th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.15). The business had revenue of $74.79 million during the quarter, compared to the consensus estimate of $72.38 million. Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. Equities research analysts expect that Travere Therapeutics, Inc. will post -1.4 EPS for the current year.

Insider Transactions at Travere Therapeutics

In other Travere Therapeutics news, insider Jula Inrig sold 2,066 shares of the firm’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $19.10, for a total transaction of $39,460.60. Following the sale, the insider now directly owns 59,883 shares of the company’s stock, valued at $1,143,765.30. This trade represents a 3.34 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Sandra Calvin sold 54,244 shares of the company’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $25.00, for a total value of $1,356,100.00. Following the completion of the transaction, the chief accounting officer now directly owns 54,410 shares of the company’s stock, valued at approximately $1,360,250. This trade represents a 49.92 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 206,335 shares of company stock worth $4,453,012 in the last three months. Corporate insiders own 4.06% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. bought a new stake in shares of Travere Therapeutics during the fourth quarter valued at approximately $31,000. Public Employees Retirement System of Ohio grew its stake in Travere Therapeutics by 102.0% during the fourth quarter. Public Employees Retirement System of Ohio now owns 102,756 shares of the company’s stock valued at $1,790,000 after acquiring an additional 51,876 shares in the last quarter. Voloridge Investment Management LLC increased its holdings in Travere Therapeutics by 33.6% in the 4th quarter. Voloridge Investment Management LLC now owns 1,007,197 shares of the company’s stock valued at $17,545,000 after acquiring an additional 253,402 shares during the last quarter. Twinbeech Capital LP purchased a new stake in Travere Therapeutics in the 4th quarter worth $177,000. Finally, Two Sigma Advisers LP boosted its holdings in shares of Travere Therapeutics by 34.3% during the 4th quarter. Two Sigma Advisers LP now owns 967,500 shares of the company’s stock valued at $16,854,000 after purchasing an additional 247,100 shares during the last quarter.

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.